Marina Wolfson Net Worth

The estimated Net Worth of Marina Wolfson is at least 3.71 千$ dollars as of 28 July 2021. Ms. Wolfson owns over 3,750 units of BiomX Inc stock worth over 3,713$ and over the last 5 years she sold PHGE stock worth over 0$. In addition, she makes 0$ as Principal Financial Officer、 Vice President - Finance and Operations at BiomX Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Wolfson PHGE stock SEC Form 4 insiders trading

Marina has made over 1 trades of the BiomX Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently she bought 3,750 units of PHGE stock worth 15,000$ on 28 July 2021.

The largest trade she's ever made was buying 3,750 units of BiomX Inc stock on 28 July 2021 worth over 15,000$. On average, Marina trades about 417 units every 0 days since 2020. As of 28 July 2021 she still owns at least 3,750 units of BiomX Inc stock.

You can see the complete history of Ms. Wolfson stock trades at the bottom of the page.

Marina Wolfson biography

Marina Wolfson serves as Principal Financial Officer, Vice President - Finance and Operations of the Company. She has served as the Vice President of Finance and Operations of the Company since December 2019. Ms. Wolfson’s experience includes working with large pharmaceutical and hi-tech companies, as well as venture capital funds. Prior to joining the Company, Ms. Wolfson worked as Vice President of Finance at BioView Ltd. (TASE) from 2010 to 2019 and a senior auditor at Ernst & Young, an international auditing and business advisory firm from 2007 to 2010. Ms. Wolfson is a certified public accountant in Israel and holds a B.A in Economics and Accounting (with honors) and an MBA (with honors, specialty in finance) from Ben-Gurion University.

How old is Marina Wolfson?

Marina Wolfson is 36, she's been the Principal Financial Officer、 Vice President - Finance and Operations of BiomX Inc since 2020. There are 13 older and no younger executives at BiomX Inc. The oldest executive at BiomX Inc is Alan Moses, 72, who is the Independent Director.

What's Marina Wolfson's mailing address?

Marina's mailing address filed with the SEC is C/O BIOMX INC., 22 EINSTEIN ST., FLOOR 4, , NESS ZIONA,, L3, 7414003.

Insiders trading at BiomX Inc

Over the last 5 years, insiders at BiomX Inc have traded over 332,366$ worth of BiomX Inc stock and bought 1,036,414 units worth 787,614$ . The most active insiders traders include James Edeerfield Management...、Chidozie Ugwumba、Erez Chimovits. On average, BiomX Inc executives and independent directors trade stock every 68 days with the average trade being worth of 533,749$. The most recent stock trade was executed by James Edeerfield Management... on 15 July 2024, trading 11,766,000 units of PHGE stock currently worth 11,648,340$.

What does BiomX Inc do?

biomx is a microbiome drug discovery company developing customized phage therapies that target and destroy harmful bacteria in chronic diseases such as inflammatory bowel disease (ibd) and cancer. we discover and validate proprietary bacterial targets and customize our natural and engineered phage compositions against these targets. the company’s platforms use computational and synthetic biology and cutting-edge research from profs. rotem sorek, ph.d., eran elinav, m.d., ph.d., and eran segal, ph.d., of the weizmann institute of science; and professor timothy k. lu, m.d., ph.d., of the massachusetts institute of technology. investors in the company include orbimed israel incubator lp, johnson & johnson development corporation inc., takeda ventures, inc., seventure partners, mirae asset global investments, and sbi.

Complete history of Ms. Wolfson stock trades at BiomX Inc

BiomX Inc executives and stock owners

BiomX Inc executives and other stock owners filed with the SEC include:

• Jonathan Solomon,
  Chief Executive Officer, Director
• Sailaja Puttagunta,
  Chief Medical Officer
• Assaf Oron,
  Chief Business Officer
• Dr. Merav Bassan Ph.D.,
  Chief Devel. Officer
• Russell Greig,
  Independent Chairman of the Board
• Lynne Sullivan,
  Independent Director
• Paul Sekhri,
  Independent Director
• Alan Moses,
  Independent Director
• Jonas Grossman,
  Independent Director
• Gbola Amusa,
  Independent Director
• Merav Bassan,
  Chief Development Officer
• Marina Wolfson,
  Principal Financial Officer, Vice President - Finance and Operations
• Dr. Regis A. Vilchez M.D., Ph.D.,
  Sr. VP & Head of Clinical Devel.
• Dr. Inbar Gahali-Sass,
  VP of Platform R&D
• Dr. Timothy K. Lu M.D., Ph.D.,
  Scientific Founder
• Dr. Eran Elinav M.D., Ph.D.,
  Scientific Founder
• Inbal Benjamini-Elran,
  VP of HR
• Noel Kurdi,
  VP of Investor Relations & Strategy
• Prof. Timothy K. Lu,
  Scientific Founder
• Dr. Eran Elinav,
  Scientific Founder
• Prof. Rotem Sorek Ph.D.,
  Scientific Founder
• Assaf Oron,
  Chief Bus. Officer
• Yaron Breski,
  Director
• Erez Chimovits,
  Director
• Thomas Layton Walton,
  10% owner
• Eddie Williams,
  Director
• Kerry Mountain Wood Llc Pro...,
  
• Israel Bio Fund Gp Limited ...,
  
• Chidozie Ugwumba,
  
• Susan Blum,
  Director
• Gregory Louis Merril,
  Director
• Jonathan S Leff,
  Director
• Jesse Goodman,
  Director
• James Edeerfield Management...,
  
• Israel Bio Fund Gp Limited ...,
  
• James Edeerfield Management...,
  
• Jason M. Marks,
  Director
• Michael E. Dambach,
  Director
• Fibrosis Foundation Cystic,